09 Dec 2019
Singapore, 09 December 2019 – The threat of infectious diseases, such as Nipah virus, spreading across borders has increased substantially as a result of the ease of global travel. Nipah virus experts and stakeholders gather at the first international conference to commemorate the 20th anniversary of the virus’ discovery and to discuss innovative and effective solutions to combat the threat to global health security posed by Nipah virus.
Duke-NUS Medical School (Duke-NUS) and the Coalition for Epidemic Preparedness Innovations (CEPI) are co-hosting The Nipah Virus International Conference 2019 on December 9 and 10. The conference brings together Nipah experts and global health stakeholders to review past Nipah outbreaks, discuss the latest developments in diagnostics, vaccines and therapeutics, and foster greater international collaboration.
Guest-of-honour Dr Lam Pin Min, Senior Minister of State, Ministry of Transport and Ministry of Health, Singapore, will deliver the opening address. The conference guests include leaders and representatives from the Ministry of Health (Singapore), the World Health Organisation (WHO), Ministry of Health (Malaysia), the U.S. National Institutes of Health (NIH), Ministry of Social and Family Development (Singapore), Duke-NUS, CEPI, SingHealth and other key stakeholders from the healthcare and biomedical ecosystem in Singapore.
Nipah virus was first identified in 1999 during a large outbreak affecting Malaysia and Singapore. The virus is one of eight categories of diseases that the WHO has identified as epidemic threats in need of prioritisation. Over the past 20 years, the virus has continued to spread over thousands of kilometres to Bangladesh and India.
Nipah is a zoonotic virus, which means that it can be spread to humans from animals. It is spread primarily by bats (specifically Pteropus fruit bats) and pigs. It can also be transmitted through contaminated food and directly from person to person.
The virus causes severe disease, with recorded mortality rates in Malaysia, Bangladesh and India of between 40 and 90 percent. In 2001, the virus was detected in Bangladesh and since then, frequent outbreaks have occurred in the country. An outbreak in Kerala, India, in 2018 claimed 17 lives.
Director of Duke-NUS’ Emerging Infectious Diseases Programme and Co-Chairman of the conference’s organising committee
One of the ways the conference aims to achieve that is by facilitating interaction between clinicians, veterinarians, scientists and public health experts from the region and beyond. Discussions such as these would help enormously in the communication, cooperation and collaboration between animal and human public health agencies to ensure that Nipah never becomes a global pandemic.
CEO of CEPI
WHO and the National Institute of Allergy and Infectious Diseases, one of the U.S. National Institutes of Health, are also key sponsors of this conference.
Duke-NUS is Singapore’s flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted ‘Clinicians Plus’ poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and nine centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore’s largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. For more information, please visit www.duke-nus.edu.sg
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has reached over US$750 million of its $1 billion funding target. CEPI’s priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invests in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (ie, Disease X). To date, CEPI has committed to investing over $456 million in vaccine and platform development. Learn more at www.cepi.net. Follow us at @CEPIvaccines.
Lekshmy Sreekumar, Ph.D., Communications, Duke-NUS Medical School
Tel: +65 65161138
Email: [email protected]
Rachel Grant, Director of Communications and Advocacy, CEPI
Email: [email protected]
Jodie Rogers, Communications Officer, CEPI
Tel: +44(0)79 793 57 459
Email: [email protected]